Does early disease progression predict survival after first line‐treatment of Waldenström macroglobulinemia?. Issue 3 (1st May 2022)

• Record Type: Journal Article
• Authors: Labreuche, Julien; Assouan, Deborah; Durot, Eric; Tomowiak, Cecile; Roos‐Weil, Damien; Toussaint, Elise; Bijou, Fontanet; Lemal, Richard; Brion, Annie; Laribi, Kamel; Ysebaert, Loic; Duhamel, Alain; Morel, Pierre
• Is Part Of: Hematological oncology. Volume 40:Issue 3(2022)
• Page Start: 400
• Page End: 408
• Publication Date: 2022-05-01
• Subjects: progression -- survival -- Waldenström macroglobulinemia; Hematological oncology -- Periodicals; Hematology; Medical Oncology; 616.99418005
• DOI: 10.1002/hon.2996
• Languages: English
• ISSNs: 0278-0232

Abstract

Abstract: In symptomatic Waldenström macroglobulinemia (sWM) patients, prognosis is assessed with the international prognostic scoring system (IPSSWM). In follicular lymphoma and other B‐cell and T‐cell lymphomas, disease progression within 24 months (POD24) or (in patients without POD24) after 24 months has been proposed as the start date for stratifying subsequent survival. In the present report, we assessed in a large series of 472 sWM patients, the prognostic value of this new dynamic endpoint already reported in many other lymphomas subtypes. The 3 year subsequent survival for patients with POD24 was 75% and 93% for patients without POD24. In sWM patients, departure from the proportional hazards assumption complicated this analysis. In patients without POD24, the median subsequent progression‐free survival time of 43 months accounted for favorable outcome, whereas survival after progression was not influenced by the time to progression. In addition, sensitivity analysis showed that the baseline IPSSWM score also influenced survival after POD24. In sWM patients, we conclude that the apparent difference in survival after POD24 or the 24 months time‐point (in patients without POD24) is mainly explained by the prolonged subsequent progression free survival of latter patients. Indeed, the mortality after progression is not influenced by the time to this event.